Theranostics Using Antibodies and Antibody-Related Therapeutics
暂无分享,去创建一个
I. C. Kok | Mathilde Jalving | Marjolijn N. Lub-de Hooge | E. D. de Vries | R. Fehrmann | M. L. Lub-de Hooge | A. Brouwers | M. Jalving | Rudolf S.N. Fehrmann | Elisabeth G.E. de Vries | Adrienne H. Brouwers | Kirsten L. Moek | Danique Giesen | Iris C. Kok | Derk Jan A. de Groot | D. D. de Groot | D. Giesen | K. Moek
[1] Simon-Peter Williams. Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging , 2012, The AAPS Journal.
[2] E. D. de Vries,et al. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel–Lindau Disease , 2016, The Journal of Nuclear Medicine.
[3] R. Boellaard,et al. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] E. D. de Vries,et al. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts , 2015, Oncotarget.
[5] Emily B. Ehlerding,et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab , 2016, The Journal of Nuclear Medicine.
[6] B. Gulyás,et al. EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD) , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[7] George Sgouros,et al. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. , 2016, Cancer research.
[8] A. Giusti,et al. 177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice , 2014, PLoS ONE.
[9] P. Peddi,et al. Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment , 2016, OncoTargets and therapy.
[10] Jong-Hyeon Jeong,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Meyer,et al. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody , 2016, The Journal of Nuclear Medicine.
[12] Kim Van der Heiden,et al. Folate Receptor–Targeted Single-Photon Emission Computed Tomography/Computed Tomography to Detect Activated Macrophages in Atherosclerosis: Can It Distinguish Vulnerable from Stable Atherosclerotic Plaques? , 2014, Molecular imaging.
[13] Sharon S. Hori,et al. Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope. , 2015, Radiology.
[14] R. Boellaard,et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer , 2015, Oncotarget.
[15] C. Swanton,et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients , 2014, Clinical Cancer Research.
[16] L. Massuger,et al. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients , 1996, International journal of cancer.
[17] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[18] Wojciech G. Lesniak,et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors , 2016, Oncotarget.
[19] Wojciech G. Lesniak,et al. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. , 2016, Bioconjugate chemistry.
[20] E. Oosterwijk,et al. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] B. Bonnotte,et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. , 2014, Cancer research.
[22] E. D. de Vries,et al. Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM , 2016, The Journal of Nuclear Medicine.
[23] P. Lambin,et al. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach , 2016, Oncotarget.
[24] W. Oyen,et al. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. , 2015, Cancer research.
[25] A. Scott,et al. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] O. Hoekstra,et al. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment , 2015, Clinical Cancer Research.
[27] R. Boellaard,et al. Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer , 2014, EJNMMI Research.
[28] A. Hauschild,et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.
[29] N. van Bruggen,et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma , 2009, The Journal of pathology.
[30] G. V. van Dongen,et al. Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.
[31] V. Kaklamani,et al. HER2-Positive Breast Cancer , 2012, Drugs.
[32] P. Kufer,et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. , 2006, Journal of immunotherapy.
[33] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[34] E. D. de Vries,et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] H. Hollema,et al. 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment , 2015, The Journal of Nuclear Medicine.
[36] Akihiko Osaki,et al. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT , 2016, The Journal of Nuclear Medicine.
[37] G. V. van Dongen,et al. Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma , 2017, The Journal of Nuclear Medicine.
[38] Steven P. Larson,et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] W. Oyen,et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] M. Bartholomä,et al. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers , 2016, Theranostics.
[41] E. D. de Vries,et al. Antibody positron emission tomography imaging in anticancer drug development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. D. de Vries,et al. 111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment , 2014, Molecular imaging.
[43] E. D. de Vries,et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. , 2007, European journal of cancer.